Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

Biopharma giant Gilead Sciences will shut down its office in Seattle’s Eastlake neighborhood, the company confirmed to ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...

FOSTER CITY, Calif., November 08, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and ...